This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7149463.stm

The article has changed 9 times. There is an RSS feed of changes available.

Version 0 Version 1
'Bubble boy' develops leukaemia 'Bubble boy' develops leukaemia
(10 minutes later)
One of the boys with no immune system being treated with pioneering gene therapy at Great Ormond Street has developed leukaemia, his doctors say.One of the boys with no immune system being treated with pioneering gene therapy at Great Ormond Street has developed leukaemia, his doctors say.
They said cancer was an "acknowledged risk" of this treatment for X-SCID, which is commonly known as "boy in the bubble syndrome".They said cancer was an "acknowledged risk" of this treatment for X-SCID, which is commonly known as "boy in the bubble syndrome".
A trial in France of the same therapy was halted in 2002 after three of ten children developed leukaemia.A trial in France of the same therapy was halted in 2002 after three of ten children developed leukaemia.
Ten children with X-SCID have so far been treated at the London hospital.Ten children with X-SCID have so far been treated at the London hospital.
All of these children "have seen clinical benefit", Professor Adrian Thrasher and Professor Bobby Gaspar, consultant immunologists on the gene therapy programme, said in a statement.
"This unfortunate event is the first such development on our programme."
X-SCID is caused by mutations in the IL2RG gene, which governs the behaviour of a protein involved in the development of a number of immune system cells.
Without the protein, the cells cannot develop normally, and are unable to protect the body.
The gene therapy works by replacing a defective gene.
French findings
But there had been warnings that there was a risk of cancer.
A US study last year published last year looked at the long-term effect of infecting the IL2RG gene into mice: A third of the animals developed a form of cancer, with most doing so when they were about 10 months old.
A few years previously a French trial was halted prematurely after three of ten boys treated were diagnosed with T-Cell leukaemia.
While nine of them had been cured of their original condition, French doctors said more work needed to be done to improve the safety of the treatment.
Last year, doctors at Great Ormond Street dismissed the findings of the US study as "unhelpful".
Professor Thrasher said then: "This is a very preliminary study published in an incomplete form.
"The researchers have taken artificially high doses of these genes and given them to animals.
"I'm not sure how it is relevant to human treatment.
"We know already that, in lower doses, the gene therapy does not have that effect."